FDA approves new nonopioid pain medication, hailed a 'triumph'
The US Food and Drug Administration has approved a new, nonopioid pain medication for treating moderate to severe acute pain. Vertex Pharmaceuticals’ suzetrigine, which will be marketed under the name Journavx, targets specific sodium channels that help pass signals on from the site of pain.
5d
Vanda Pharmaceuticals Inc. recently made a significant move by filing a new drug application for Tradipitant. The application, targeted at addressing motion sickness, was publicized through a social ...
Atara Biotherapeutics said the U.S. Food and Drug Administration placed a clinical hold on its active investigational new drug applications. The biotechnology company said the FDA put a hold on its ...
An investigational higher dose of spinal muscular atrophy drug nusinersen gains attention as the FDA and European Medicines ...
GlobalData on MSN10d
Stealth faces another hurdle as FDA delays decision on Barth syndrome drugThe FDA rejected the company’s initial NDA in 2021, citing the lack of an adequate trial to demonstrate efficacy.
Lisdexamfetamine Dimesylate is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and ...
GSK (GSK) announced that new drug applications have been accepted for review by the China National Medical Products Administration and submitted to the Japanese Ministry of Health, Labour and ...
Inc. stock despite strong Phase 2b data. Click for my updated look at MNMD stock and its market opportunities.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback